PRODUCT INFORMATION



Prostaglandin I₃ (sodium salt)

Item No. 18300

CAS Registry No.		\frown
Formal Name:	6,9α-epoxy-11α,15S-dihydroxy- prosta-5Z,13E,17Z-trien-1-oic	
	acid, monosodium salt	0 COO-
Synonym:	PGI ₃	/ • Na ⁺
MF:	C ₂₀ H ₂₉ O ₅ ● Na	
FW:	372.4	
Purity:	≥95%	
Supplied as:	A lyophilized powder	но
Storage:	-20°C	OH
Stability:	≥4 years	
Special Conditions: Hygroscopic		
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

PGI₃ is supplied as a lyophilized powder soluble in water. It is unstable at neutral or acidic pH. On exposure to open air, the compound will absorb moisture and hydrolyze rapidly to 6-keto PGF_{1a} . An aqueous stock solution of PGI_3 can be prepared by dissolving the crystalline solid directly in basic buffers (pH >10.2). The solubility of PGI₂ in PBS (pH >10.2) is approximately 10 mg/ml. Solutions of PGI₂ at physiologic pH and room

temperature will have a half-life from 1 to 12 minutes depending on buffer concentration.^{1,2} PGI₃ is a prostacyclin analog. Δ^{17} -2,3-dinor-6-keto Prostaglandin F_{1a} is the major urinary metabolite of PGI₃.³ Therefore, the measurement of Δ^{17} -2,3-dinor-6-keto Prostaglandin F_{1a} by GC/MS is used as a marker of the in vivo production of PGI₃.3

Description

PGI₃ is synthesized from EPA by COX and PGI synthase. PGI₃ has a short in vivo half-life and is hydrolyzed to Δ^{17} -6-keto PGF_{1a}. The platelet and vascular activity of PGI₃ is equivalent to that of PGI₂.^{3,4}

References

- 1. Stehle, R.G. Physical chemistry, stability, and handling of prostaglandins E_2 , $F_{2\alpha}$, D_2 and I_2 : A critical summary. Methods Enzymol. 86, 436-459 (1982).
- Moncada, S. Biology and therapeutic potential of prostacyclin. Stroke 14(2), 157-168 (1983). 2.
- Mann, N.J., Warrick, G.E., O'Dea, K., et al. The effect of linoleic, arachidonic, and eicosapentaenoic acid supplementation of prostacyclin production in rats. Lipids 29(3), 157-162 (1994).
- 4. Johnson, R.A., Lincoln, F.H., Nidy, E.G., et al. Synthesis and characterization of prostacyclin, 6-ketoprostaglandin F_{1g}, prostaglandin I₁, and prostaglandin I₃. J. Am. Chem. Soc. 100(24), 7690-7704 (1978).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM